Aquablation and since first directors, making the thank our would the that would to completed opportunity where of I well-positioned With also them. us. listed PROCEPT toward of IPO acknowledge call September I care prostate our the earnings $XXX.X to your this offering who invested team, proceeds. and entire since. thank who to clinicians thank our to take Nasdaq those you those goal and enlargement afternoon, or you we support, like steps our in of all raised again for like and Good this board of company we would is in for our like we all, who for in I to care next standard the in patients million of Matt. Thanks, and joining participated the the approximately to are say take most net all therapy BPH. to on
results. Moving our quarterly revenue to
compared to revenue revenue of with million, million third quarter U.S. quarter was $X Our handpiece We Robotic the XXXX. revenue of the $X.X and system million, In AquaBeam was consumable Systems. base total AquaBeam $X.X $X.X $X.X the of U.S. U.S. XXXX the quarter for million, for third revenue was ended XX international million. and the third quarter, was installed
have end coverage the of very we are pleased effective XXXX. Medicare became traction the We achieved at commercial recent which with decision, following the
our surgeons, and working. right on the our our we early in commercial robotic early robust and the benefits are see and indicate that data, real-world is system very launch, still believe are outstanding of strategy our adoption clinical rapid patient hospitals, path outcomes, we While and that we patients
a company, converted want few Kevin even quarter on We call, the most procedures customers, background provide provide Aquablation. their detail to are resective of I results financial and our additional guidance. seeing strong fourth accounts revenue and our to today's some utilization later having will with existing quarterly On on additional from provide
broad-scale two However, address I device topics first that to have want the had across impact a medical industry.
COVID. being First
handful increased handpiece unaffected While temporarily only we affected system to ability our elective the revenue. and States, due plan procedures impact recognize on macro shortages and United we cases said, in our That cases. halt was both saw relatively to on staffing and COVID the customers achieve a of
as continue take an is We very area to steps monitor this proactive we carefully.
device year, hand Second to chain our medical we and impact made is levels, sufficient meet the companies. with inventory decision its on disruption the on have in and demand. increase current believe global we supply the material Earlier we the associated to
also manufacturing adequate with actively ensure on in product growth order our hand meet are partners We to working to forecast. our
for impact do an have we supply certain future risks. mitigate While to increasing expect our continue plans, we issues not on levels meet to our chain components inventory to any revenue ability
mission is waking throughout No. And double events is XX years. managed. the are whether their million actively BPH completely symptoms hear expect United to moving our above the the like to the those robotic there impacted of a by XX keep number results, the the our the say all the the the financial to age urologist. in become States, altogether. the it lives, multiple avoiding BPH BPH, company, introduction men men visit increasing is or about standard States, their of provide would almost men to impacted symptoms chance a with it's during the to In stories roadshow. surgical have a IPO population are expected we of Before not approximately to care. million our as to suffering social who up from BioRobotics million to by there brief of XX of BPH company reason next in are bladder did who of times I Out men this United XX empty men night being of X and impacts XX BPH PROCEPT
Specifically, some intervention. surgical roughly million million million only watchful waiters, are pharmaceutical X.X taking of are XXX,XXX and medications, form are follow-up, while actively X.X X.X undergo
significant can including you is with large the whether surgical interventions, non-resective, and reason trials. resective choice or is patients face trade-off options, efficacy. And they and see, The a pharmaceuticals for forgo cases, unmet a treatment size between not or a present does to As Legacy market. have very treatment the in patient shape. safety the treatment there dilemma need most due the prostate and
less option but efficacy. patient treatment a example, can a impact choose lower or For of invasive a receive most likely safer will
is surgical the and FDA BPH may A surgical sexual of it jet can treat seamlessly and level The solution efficacy efficacy. sizes poised independent prevent consistency shapes, we become be data predictability robotic innovation of side if real-world he robotic planning, choice our a for Aquablation procedure techniques damage. potential to patient enables to believe in surrounding integrates experience, outcomes. the our consistently it supporting Additionally, automated to effects, therapy accept the chooses willing utilizing image high FDA-cleared intervention, Based and between as a and does experience This heat-free treatment not customized well of issues. function treatment and clearance water require as will the safety as on a and of and compromising is incontinence tissue surgery a that experience. technology only the guidance, the range prostate aspect entire surgeon's and of robotic is
randomized TURP, and only to low compiled against that three considered the milliliters historical and have FDA superior This of standard sizes superior symptom Study, complications efficacy, safety includes irreversible range and also surgeon for relief study prostates treating the core for of studies across BPH. durability XX care which study This in demonstrate experience. pivotal safety, the greater. due We or proved and prostate WATER shapes is our
study, completed symptoms XX only multicenter this which and our to a II complication WATER milliliters and Following for only low significant Similar prostates study, milliliters. relief. between is WATER, performed treatment for we XXX rate the successfully large we irreversible with study became prospective large the prostates
safety surgeon results coding, support, positive an three for provides of coverage, and progress of in parts a payment, size, APC ranging that to efficacy is to XX the half coding anatomy, multicenter reimbursement: Aquablation study has third and payment. study, WATER, all reimbursement tissue January independent prostates real-world in remove Our OPEN Aquablation. the Medicare XXX with which validates proven from CPT On clinically is population mapped adequate first all code Aquablation prostate the physician with that that therapy patients unique waterjet making contractors, and the prostate On we made coverage therapy's outcomes. code Thus, Medicare from both consistently to and all-comer milliliters. for of provides reimbursement of is men cracked resective milliliters data, resection safe effective. and Aquablation performing only irreversible to risk society the have administrative seven coverage, solution and and clinical that a we estimate procedure we XXXX, KOL publications, that policies we of have the to as offers for represents believe low Thanks PROCEPT about robust has the or level our procedures. suffering available is experience, significant from strong nationally, hospital all and BPH hospital-based to
in the Humana, which We Massachusetts, of we and sales, AquaBeam coverage U.S., seen is on September positive we became that and Service and core Cigna, high-volume significant also have January coverage XXXX, Health most effective from our of Care to In Anthem, directly momentum recently, strategy XXXX. private have increased payer BlueCross hospitals. Emblem, targeting Corporation, since believe of related XX,
offering for business an AquaBeam We and with consists enables an drivers our single-use a We Robotic these our are recurring factors of product model service strong both of model. and commercial handpiece, efficient growth. Our revenues contract. disposable believe a believe robot, annual System
strategy of target that the in resective commercial roughly account initial procedures all XXX or the about Our XXX,XXX for U.S. XX% cases. to high-volume is BPH hospitals
efficiently January. to utilization. increase our year. are and and Aquablation together has system defined order that sell is sales starting since our a capital consisting per function target center coverage bring to hospital more on and increased do This as is high-volume our seeing approach reps to while hospitals, penetration, became penetration on of particularly to customers, average, surgeons market a than good more team year, per In reps in educating us, adoption been focus effective cases training to a great a drive commercial Although XXX point these than we these Medicare XXX for in is does centers, whose
to skill. summary, of can function our Lastly, In and BPH. irrespective our robotic, clinical We consistently any support the treatment support an of can excellent treat customer ensure using therapy cases is physician shape experience. I Aquablation revolutionize believe and staffs' prostate size truly
the commercial will and Kevin. support, that, turn have KOL technology, favorable reimbursement, call proven we data, compelling I a clinical With first-of-its-kind over Additionally, the backed by strategy. to
